Drug and Device Accountability Act of 2009
Latest action · Apr 23, 2009 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedApr 23, 2009
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Drug and Device Accountability Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise provisions regarding the registration of drug and device establishments, including to: (1) expand the information required to be included in a registration; and (2) provide for risk-based inspections.
Includes in the definition of "drug" a precursor ingredient.
Requires the Secretary of Health and Human Services (HHS) to assess the registration exemption for manufacturers of harmless inactive ingredients that become components of drugs.
Deems a drug to be adulterated if certain conditions related to verification of identity and purity, identification of establishments, consistency with current manufacturing technologies, and conformity with good distribution and import practices are not met.
Deems a drug or device to be misbranded unless certain conditions related to labeling for country of manufacture and provision of required information on importation are met.
Sets forth provisions governing importation of a drug and its components.
Sets forth required actions, including cessation of distribution, if there is a reasonable probability that a drug intended for human use would cause serious, adverse health consequences or death.
Establishes actions manufacturers must take regarding any defective drug.
Sets forth additional required certifications for submissions related to drugs and devices regarding accuracy and personal knowledge of information submitted.
Establishes whistleblower protection for employees providing information regarding a drug, biological product, or device.
Requires the Secretary to contract with the Institute of Medicine to evaluate: (1) the organizational structure and operations of the Food and Drug Administration (FDA) with respect to the review of medical devices for clearance and for premarket approval under FFDCA; and (2) the analytical and methodological tools used to conduct such reviews.
Directs the Secretary to establish a corps of inspectors dedicated to inspections of foreign establishments and facilities.
Sets forth enforcement provisions.
Cosponsors 1
Members who signed on, in the order they did. All signed on Apr 23, 2009.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-IA | Chuck Grassley | Original | Apr 23, 2009 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred Apr 23, 2009 |
Actions 2
Everything that happened, newest first.
- Apr 23, 2009Introduced in Senate
- Apr 23, 2009Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Debate and remarks S4686 | Chuck Grassley R-IA | Apr 23, 2009 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety and quality of medical products and enhance the authorities of the Food and Drug Administration, and for other purposes.
- Short Titles as Introduced
- Drug and Device Accountability Act of 2009
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Employment discrimination and employee rights
- Executive agency funding and structure
- Food and Drug Administration (FDA)
- Government information and archives
- Government studies and investigations
- Health
- Health technology, devices, supplies
- Licensing and registrations
- Prescription drugs
- Product safety and quality
- Trade restrictions
- User charges and fees
Text 1
Each version as it was printed, newest first.
- Apr 23, 2009Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.